Results 21 to 30 of about 9,615 (165)

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

open access: yesPathology and Oncology Research, 2022
Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse.
Ferenc Takács   +19 more
doaj   +1 more source

Mechanism of Covalent Binding of Ibrutinib to Bruton’s Tyrosine Kinase revealed by QM/MM Calculations [PDF]

open access: yes, 2020
Ibrutinib is the first covalent inhibitor of Bruton’s tyrosine kinase (BTK) to be used in the treatment of B-cell cancers. Understanding the mechanism of covalent inhibition is crucial for the design of safer and more selective covalent inhibitors that ...
Angus, Voice   +4 more
core   +1 more source

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

open access: yesCancer Medicine, 2022
Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy
Yuchen Zhang   +21 more
doaj   +1 more source

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus

open access: yesHaematologica, 2020
The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive aspergillosis. The mechanisms
Damien Blez   +10 more
doaj   +1 more source

Ibrutinib is not an effective drug in primografts of TCF3-PBX1

open access: yesTranslational Oncology, 2020
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-
Cesca van de Ven   +4 more
doaj   +1 more source

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

open access: yesJournal of Neuroinflammation, 2018
Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling.
Hye Yeon Nam   +8 more
doaj   +1 more source

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells [PDF]

open access: yesBrazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases.
Fengbo Jin   +8 more
doaj   +1 more source

Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia Case report and literature review [PDF]

open access: yes, 2019
Introduction: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ...
Albattah, A   +20 more
core   +1 more source

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

open access: yesAdvances in Hematology, 2022
Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation.
Januario E. Castro   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy